$-0.11 EPS Expected for Xenon Pharmaceuticals Inc. (XENE)

February 24, 2018 - By Clifton Ray

 $ 0.11 EPS Expected for Xenon Pharmaceuticals Inc. (XENE)

Analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to report $-0.11 EPS on March, 14.They anticipate $0.21 EPS change or 65.63 % from last quarter’s $-0.32 EPS. After having $-0.43 EPS previously, Xenon Pharmaceuticals Inc.’s analysts see -74.42 % EPS growth. The stock decreased 1.20% or $0.04 during the last trading session, reaching $3.7. About 29,929 shares traded. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has declined 39.94% since February 24, 2017 and is downtrending. It has underperformed by 56.64% the S&P500.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Ratings Coverage

Among 5 analysts covering Xenon Pharmaceuticals (NASDAQ:XENE), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Xenon Pharmaceuticals had 14 analyst reports since August 11, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Monday, June 12 report. The firm has “Buy” rating given on Friday, October 21 by Stifel Nicolaus. Canaccord Genuity maintained Xenon Pharmaceuticals Inc. (NASDAQ:XENE) rating on Tuesday, June 27. Canaccord Genuity has “Buy” rating and $500 target. Jefferies maintained it with “Buy” rating and $5.0 target in Monday, September 11 report. The company was upgraded on Wednesday, August 19 by Zacks. The firm has “Sell” rating given on Wednesday, September 2 by Zacks. The stock has “Buy” rating by Guggenheim on Monday, September 26. The stock of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) earned “Buy” rating by Jefferies on Friday, August 4. The rating was reinitiated by Jefferies on Monday, March 13 with “Buy”. Jefferies reinitiated the shares of XENE in report on Friday, October 30 with “Buy” rating.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company has market cap of $66.59 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It currently has negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

More notable recent Xenon Pharmaceuticals Inc. (NASDAQ:XENE) news were published by: Globenewswire.com which released: “Xenon Pharmaceuticals Announces Pricing of $30 Million Public Offering of …” on September 08, 2016, also Globenewswire.com with their article: “Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in …” published on March 24, 2017, Globenewswire.com published: “Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update” on March 08, 2017. More interesting news about Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were released by: Globenewswire.com and their article: “Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the …” published on February 20, 2018 as well as Seekingalpha.com‘s news article titled: “Xenon Pharmaceuticals’ (XENE) CEO Simon Pimstone on Q2 2017 Results – Earnings …” with publication date: August 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.